Skip to search formSkip to main contentSkip to account menu

rufloxacin

Known as: 9-fluoro-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]thiazino[2,3,4-ij]quinoline-6-carboxylic acid, 9-fluoro-10-(N-(4'-methyl)piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido(1,2,3de)-1,4-benzothiazine-6-carboxylic acid 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
The fluoroquinolone Rufloxacin (RFX) is active as specific inhibitor of bacterial gyrase. The adverse effects of the… 
1993
1993
The concentrations of rufloxacin in the bronchial mucosal, pulmonary epithelial lining fluid and alveolar macrophages were… 
1993
1993
The pharmacokinetics of rufloxacin were investigated in normal subjects and in patients with various degrees of renal failure… 
1991
1991
The pharmacokinetics of rufloxacin after a single 400 mg oral dose were studied in eight volunteers, measuring plasma… 
1991
1991
Rufloxacin is a new long-acting, once-daily quinolone antibacterial agent. We evaluated inter- and intrasubject variations in… 
1991
1991
Rufloxacin is a new broad-spectrum fluoroquinolone antibacterial agent. The pharmacokinetics and safety of rufloxacin were… 
1991
1991
The penetration of rufloxacin into prostatic tissue and prostatic fluid was investigated in 16 patients undergoing elective… 
1991
1991
The in vitro activity of rufloxacin (MF 934), a new broad-spectrum fluoroquinolone, was tested against 1,032 gram-positive and… 
1989
1989
Rufloxacin (MF-934) is a new quinolone which shows in vitro antibacterial activity against E. coli, Salmonella, Klebsiella…